Skip to main content
Top

Chronic Pain in the Cancer Survivor

Published in:

Abstract

Purpose of Review

As cancer survivorship continues to rise, attention has increasingly turned to the long-term sequelae of oncologic treatment. While interventions such as chemotherapy, radiation therapy, and surgery have significantly improved survival outcomes, they are frequently associated with chronic pain syndromes that can profoundly impact quality of life. This review synthesizes current evidence and therapeutic approaches for three prevalent pain conditions in cancer survivors: chemotherapy-induced peripheral neuropathy, post-radiation pain syndromes, and post-surgical pain syndromes. Emphasis is placed on pathophysiology, diagnostic considerations, and emerging management strategies to guide clinicians in optimizing survivorship care.

Recent Findings

Evidence supports the use of duloxetine for chemotherapy-induced peripheral neuropathy. Despite the wide use of gabapentinoids and tricyclic antidepressants for chemotherapy-induced peripheral neuropathy the data is limited on efficacy. For post-radiation and post-surgical pain syndromes related to cancer, current evidence supports a multimodal approach of physical therapy, injections, and pharmacologic agents.

Summary

A personalized and multimodal approach is recommended for chronic pain in cancer survivors. Further investigations into the treatment for chronic pain syndromes in cancer survivors are critical to improve the long-term outcomes and quality of life for cancer survivors.
Title
Chronic Pain in the Cancer Survivor
Authors
Jillian Maloney
M Kraus
N Strand
G Paramanandam
R Garcia
A Badwal
O Viswanath
J Freeman
C Wie
L Misra
MW Harbell
Publication date
27-11-2025
Publisher
Springer US
Published in
Current Pain and Headache Reports / Issue 1/2025
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-025-01431-x
This content is only visible if you are logged in and have the appropriate permissions.

Case simulations: Biomarker-driven management of NSCLC (Link opens in a new window)

Do you want to assess your biomarker testing skills and management decisions? Use these simulation-based case studies based on realistic NSCLC scenarios to do so in a practical and secure environment.

Independent Medical Education Grant:
  • Bayer HealthCare Pharmaceuticals Inc.
Learn more Link opens in a new window
COMMISSIONED

How-to guide for healthcare professionals: understanding genomic reports

This educational activity was initiated, funded and co-developed by Boehringer Ingelheim and is intended for healthcare professionals in the UK and Ireland only. 

Genomic testing helps inform cancer diagnosis, prognosis, and treatment. A genomic report is generated by the laboratory carrying out next-generation sequencing to analyze biopsy samples. Access this educational microsite to learn more about typical genomic report content and how to interpret test results for patients with cancer.

NP-GB-106631 | Jan 2026

Commissioned by:
  • Boehringer Ingelheim
Learn more
Image Credits
Woman with pain in her hand/© Satjawat / Stock.adobe.com (symbolic image with model), Biomarker-driven management of NSCLC logo/© Springer Health+ IME, DNA double helix structure on a purple background/© 2025 Adobe